Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Current Investments (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Cash & Current Investments data on record, last reported at $467.7 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 13.36% year-over-year to $467.7 million; the TTM value through Dec 2025 reached $467.7 million, up 13.36%, while the annual FY2025 figure was $467.7 million, 13.36% up from the prior year.
  • Cash & Current Investments reached $467.7 million in Q4 2025 per APLS's latest filing, down from $480.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $965.3 million in Q1 2022 and bottomed at $272.4 million in Q2 2021.
  • Average Cash & Current Investments over 5 years is $500.1 million, with a median of $460.6 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: tumbled 60.82% in 2021, then skyrocketed 122.41% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $641.8 million in 2021, then fell by 13.82% to $553.1 million in 2022, then plummeted by 36.3% to $352.3 million in 2023, then rose by 17.12% to $412.6 million in 2024, then grew by 13.36% to $467.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $467.7 million in Q4 2025, $480.6 million in Q3 2025, and $371.5 million in Q2 2025.